Gitnux/Report 2026

Hormone Health Industry Statistics

The global menopause market is estimated at $19.7 billion in 2026, explore the figures behind growth, company financials and trends shaping hormone health.
10Statistics
26Sources
3Sections
1Visuals
13mRead
Hormone Health Industry Statistics
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The hormone health industry at a glance

The global menopause market is estimated at $19.7 billion in 2026, reflecting rapid expansion across hormone therapy, supplements, diagnostics, digital care and consumer health.

$19.7B[8]
Global menopause market, 2026
5.6%[8]
Menopause market CAGR, 2026–2033
37.1%[8]
North America market share, 2025
15.6%[9]
U.S. women taking symptom medication, 2025
Market size
The global menopause market was valued at $18.7 billion in 2025 and is estimated at $19.7 billion in 2026. A broader PwC estimate places the menopause-specific opportunity at approximately $10 billion–$15 billion in 2026, reflecting differences in market definitions and included categories.[8][10]
Forecast & CAGR
Grand View Research forecasts the global menopause market to reach $28.8 billion by 2033, implying a 5.6% CAGR from 2026 to 2033. PwC estimates a faster 8%–10% annual growth rate for menopause solutions through 2030.[8][10]
Market share & regions
North America accounted for 37.1% of global menopause-market revenue in 2025, making it the largest regional market. The market is also segmented across Europe, Asia Pacific, Latin America, and the Middle East and Africa.[8]
Segmentation
Dietary supplements represented 94.3% of the global menopause market by treatment in 2025, according to Grand View Research. Other industry segments include over-the-counter pharmaceutical products, prescription hormone therapy, diagnostics, care delivery, digital services, devices and employer or payer solutions.[8][10]
Trends, drivers & challenges
Growth is being driven by population aging, increased awareness, regulatory changes and demand for personalized midlife care. Despite the opportunity, treatment remains underused: in 2025, only 15.6% of U.S. women aged 40–60 with recent menopausal symptoms were currently taking prescription medication for those symptoms.[10][9]
Consumer behavior & competition
Consumer demand is shifting toward integrated care combining pharmaceuticals, supplements, symptom tracking, telehealth and at-home diagnostics. A 2026 Gallup-Pivotal survey found that only 37% of U.S. women reported a good understanding of menopause symptoms and 25% reported a good understanding of treatment options, leaving substantial room for education-led competition.[11][10]
M&A
M&A activity is expanding the delivery infrastructure for hormone health. In April 2025, LifeMD acquired assets of Optimal Human Health MD, a virtual-care provider focused on women’s health and hormone-replacement therapy; in 2026, PAI Partners and Carlyle agreed to sell women’s-health pharmaceutical company Theramex.[12][13]
Regulation
The FDA approved labeling changes for six menopausal hormone-therapy products on February 12, 2026, removing boxed-warning statements related to cardiovascular disease, breast cancer and probable dementia while retaining other product-specific safety information. The FDA said approximately 2 million U.S. women aged 46–65 received a hormone-therapy prescription in 2020.[14]
Latest news
The most significant recent regulatory development is the FDA’s February 2026 approval of revised labeling for six menopausal hormone-therapy products, following its November 2025 initiative to review and remove broad boxed-warning language. The changes are expected to support more individualized benefit–risk discussions between patients and clinicians.[14]

02 Ranking

Top 10 Companies in the Hormone Health Industry

The leading companies in the hormone health industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 18, 2026 · Next review December 18, 2026

Verdict

AbbVie stands out for hormone replacement medicines because it reports an 8.57% revenue growth and a 24.65% operating margin, while Ferring Pharmaceuticals focuses on reproductive medicines since it reported EUR 1.203 billion in 2025 Reproductive Medicine sales.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in menopause hormone medicines

    AbbVie

    US

    Ranked #1 · 9.4 · Menopause hormone medicines

    Why we picked it: It operates in endocrine and hormone replacement medicines, with revenue growth of 8.57% and a 24.65% operating margin.

  2. Leader in fertility & reproductive hormones

    Ferring Pharmaceuticals

    CH

    Ranked #2 · 9.2 · Fertility & reproductive hormones

    Why we picked it: It sells fertility and reproductive hormone medicines, anchored by EUR 1.203 billion in 2025 Reproductive Medicine sales.

  3. Leader in women’s health therapeutics

    Gedeon Richter

    HU

    Ranked #4 · 8.8 · Women’s health therapeutics

    Why we picked it: It focuses on women’s health and menopause therapies, reporting an 8.3% revenue growth and a 31.5% operating margin.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the hormone health industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

AbbVie

Menopause hormone medicines · US

9.4
2

Ferring Pharmaceuticals

Fertility & reproductive hormones · CH

9.2
3

Pfizer

Menopause hormone medicines · US

9.0
4

Gedeon Richter

Women’s health therapeutics · HU

8.8
5

Theramex

Women’s health therapeutics · GB

8.7
6

Ascendis Pharma

Endocrine and hormone replacement medicines · DE

8.7
7

Besins Healthcare

Estrogen, progesterone and testosterone therapies · FR

8.5
8

Bayer

Women’s health and reproductive medicines · DE

8.4
9

Organon

Women’s health, fertility and hormone therapies · US

8.2
10

Viatris

Generic hormone replacement medicines · US

7.7

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 18, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the hormone health industry. In Hormone Health Industry Statistics. Gitnux. https://gitnux.org/hormone-health-industry-statistics/#top-companies

report visual · Comparison

Global hormone replacement therapy market share by route of administration

Oral holds the largest share at 41.9%.

Oral41.9%
Transdermal27.8%
Parenteral20.2%
Other10.1%
source-verifiedpmarketresearch.com

04 Statistics

Market Intelligence

Market size framing matters for hormone health services. A $10 billion–$15 billion 2025 estimate covers menopause-specific solutions across care delivery, digital services, pharmaceuticals, devices, consumer health, and payer and employer solutions.

Market size and service revenue in the hormone health industry

  • $10 billion–$15 billion was the estimated 2025 global market for menopause-specific solutions, including care delivery, digital services, pharmaceuticals, devices, consumer health, and payer and employer solutions; this is a broader parent-category proxy for hormone-health services.[1]

05 Statistics

People & Workforce

Care capacity and practitioner availability show the execution constraints. Veterans Health Administration reported 220 full-time-equivalent gynecology providers delivering menopause care in fiscal 2024, up 56% from 142 in fiscal 2019.

Employment and hiring in the hormone health industry

  • 45% of 133 surveyed gender-affirming-care providers in U.S. states without restricting laws were medical practitioners in 2024; 55% were mental-health practitioners.[2]
  • 220 full-time-equivalent gynecology providers delivered menopause care in the U.S. Veterans Health Administration in fiscal 2024, up 56% from 142 in fiscal 2019.[3]
  • 3,832 full-time-equivalent women’s health primary-care providers served menopause-care delivery in the U.S. Veterans Health Administration in fiscal 2024, up 43% from 2,688 in fiscal 2019.[3]

Skills and certification in the hormone health industry

  • More than 70% of 60 responding U.S. Veterans Health Administration facilities reported needing additional support to manage veterans’ menopause symptoms in a 2023 provider-needs survey.[3]
  • 46 Women’s Health Mini-Residency sessions trained more than 1,090 VHA providers in fiscal 2025: over 700 in three national sessions and an additional 390 across 22 rural medical facilities.[3]
  • At most 0.5 Menopause Society Certified Practitioners served per 10,000 U.S. women aged 45–65, according to a 2026 clinical education paper.[4]

06 Statistics

Pricing

Published prices anchor buyer expectations for hormone-related visits and plans. Median ongoing pricing was $93 per month for estrogen-plus-progesterone plans and $150 for median first-visit fees in October 2026.

Fees and price levels in the hormone health industry

  • $93 per month was the median ongoing price for estrogen-plus-progesterone menopause-care plans from five U.S. telehealth providers, excluding medication-only estrogen plans, in October 2026.[5]
  • $122.50 per month was the median entry price among 20 U.S. online testosterone-replacement providers publishing prices, with published tiers from $25 to $340, in July 2026.[6]
  • $150 was the median first-visit fee among 552 U.S. hormone-therapy practices publishing consultation prices, based on prices read in October 2026.[7]

Key questions about the hormone health industry

What is the 2026 market size for menopause in hormone health?
The global menopause market is estimated at $19.7 billion in 2026. This follows a $18.7 billion valuation in 2025.
How fast is the menopause market growing after 2026?
Grand View Research forecasts the market to reach $28.8 billion by 2033, implying a 5.6% CAGR from 2026 to 2033. PwC also estimates an 8%–10% annual growth rate for menopause solutions through 2030.
Which companies lead the hormone health industry?
AbbVie stands out for hormone replacement medicines because it reports an 8.57% revenue growth and a 24.65% operating margin, while Ferring Pharmaceuticals focuses on reproductive medicines since it reported EUR 1.203 billion in 2025 Reproductive Medicine sales.
What technology and care delivery shifts are showing up in hormone health offerings?
Consumer demand is shifting toward integrated care combining pharmaceuticals, supplements, symptom tracking, telehealth, and at-home diagnostics. At-home testing is entering integrated offerings.
How is the hormone health market structured by category and treatment type?
Dietary supplements represented 94.3% of the global menopause market by treatment in 2025, with other segments including OTC products, prescription hormone therapy, diagnostics, care delivery, digital services, devices, and employer or payer solutions.
What regulatory change affected menopausal hormone therapy in 2026?
On February 12, 2026, the FDA approved labeling changes for six menopausal hormone-therapy products, removing boxed-warning statements related to cardiovascular disease, breast cancer, and probable dementia while retaining other product-specific safety information.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Hormone Health Industry Statistics. Gitnux. https://gitnux.org/hormone-health-industry-statistics
MLA
Samuel Norberg. "Hormone Health Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/hormone-health-industry-statistics.
Chicago
Samuel Norberg. 2026. "Hormone Health Industry Statistics." Gitnux. https://gitnux.org/hormone-health-industry-statistics.